← Browse by Condition
Medical Condition

rhabdomyosarcoma

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1

ClinicalMetric tracks all active clinical trials for rhabdomyosarcoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — rhabdomyosarcoma Clinical Trials

How many clinical trials are currently recruiting for rhabdomyosarcoma?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for rhabdomyosarcoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for rhabdomyosarcoma?
rhabdomyosarcoma research spans Phase 1 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a rhabdomyosarcoma clinical trial?
Eligibility criteria for rhabdomyosarcoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Top Sponsors
University of Wisconsin, Madison 1 trial
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 1 trial
Sun Yat-sen University 1 trial

Recruiting Clinical Trials

NCT02508038 Phase 1
Recruiting
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
Enrollment
22 pts
Location
United States
Sponsor
University of Wisconsin, Madis...
View Trial →
NCT06796543
Recruiting
Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
Enrollment
70 pts
Location
United States
Sponsor
Sidney Kimmel Comprehensive Ca...
View Trial →
NCT07584499 Phase 1
Recruiting
Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
Enrollment
51 pts
Location
China
Sponsor
Sun Yat-sen University
View Trial →

Related Conditions

ewing sarcoma (2) neuroblastoma (2) acute myeloid leukemia (1) acute lymphoblastic leukemia (1) hodgkin lymphoma (1) non hodgkin lymphoma (1) myelodysplastic syndrome (1) myeloproliferative syndrome (1) primitive neuroectodermal tumor (1) osteosarcoma (1) metastatic sarcoma (1) radiation therapy patient (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology